Zijun Y. Xu‐Monette

Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone

Tina Green, Ken H. Young, Carlo Visco et al. · Journal of Clinical Oncology · 2012 · 683 citations · Full text

Medicine, Hematology, Oncology +14

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program

Shimin Hu, Zijun Y. Xu‐Monette, Alexandar Tzankov et al. · Blood · 2013 · 679 citations · Full text

Medicine, Cancer Biology, Oncology +15

Breast Implant–Associated Anaplastic Large-Cell Lymphoma: Long-Term Follow-Up of 60 Patients

Roberto N. Miranda, Tariq N. Aladily, H. Miles Prince et al. · Journal of Clinical Oncology · 2013 · 399 citations · Full text

Medicine, Oncology, Surgery +12

Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study

Zijun Y. Xu‐Monette, Lin Wu, Carlo Visco et al. · Blood · 2012 · 391 citations · Full text

Medicine, Hematology, Oncology +14

The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation

Davide Rossi, Valeria Spina, Clara Deambrogi et al. · Blood · 2011 · 377 citations · Full text

Life Sciences, Genetics, Molecular Genetics +9